Search

Search Constraints

You searched for: Author/Creator Phillips, Tycel

Search Results

1. Pembrolizumab in relapsed or refractory Richter syndrome. (16th June 2020)

4. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Issue 15 (20th May 2021)

5. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Issue 9 (29th July 2021)

7. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Issue 11 (November 2020)

8. RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106. (19th December 2016)

9. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma. Issue 1 (6th November 2019)

10. A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T‐cell lymphomas. Issue 12 (25th September 2017)